Rigel Pharmaceuticals, Inc.

RIGL· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$46.43+1.26%

2026-09-18

Financials

Valuation Metrics

Rigel Pharmaceuticals, Inc.'s Market Cap is $859M. At end of 2025 it was $770M. Ranked #2554 of 3,121 in US market (top 82%), #1068 of 1,463 on NASDAQ (top 73%), #198 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 74%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	$859M	US#2,554/3,121 Sec#198/266
Revenue	$277M	US#2,489/3,121 Sec#100/266
Net Income	$322M	US#1,060/3,121 Sec#35/266
Total Assets	$521M	US#2,756/3,121 Sec#163/266
Net Assets	$425M	US#2,339/3,121 Sec#127/266
Value
P/E	2.67x	US#14/3,121 Sec#1/266
P/B	2.02x	US#1,243/3,121 Sec#50/266
PEG	0.01x	US#36/3,121 Sec#4/266
P/S	3.10x	US#1,731/3,121 Sec#47/266
EV/EBITDA	8.91x	US#622/3,121 Sec#18/266
FCF Yield	9.24%	US#666/3,121 Sec#20/266
Profitability
ROE	75.67%	US#55/3,121 Sec#3/266
ROA	61.78%	US#4/3,121 Sec#1/266
Op. Margin	31.45%	US#481/3,121 Sec#23/266
Revenue Growth	3.31%	US#1,968/3,121 Sec#122/266
Earnings Growth	229.08%	US#147/3,121 Sec#10/266
Financial Health
Debt Ratio	22.43%	US#252/3,121 Sec#86/266
Total Debt	$40M	US#2,648/3,121 Sec#162/266
FCF	$79M	US#1,833/3,121 Sec#65/266
Cash	$61M	US#2,499/3,121 Sec#217/266
Current Ratio	1.95x	US#1,287/3,121 Sec#224/266
Net Debt/EBITDA	-0.22x	US#489/3,121 Sec#27/266
Performance
1Y Return	32.24%	US#823/3,121 Sec#132/266
1M Return	-1.13%	US#481/3,121 Sec#53/266
From 52W High	-11.12%	US#911/3,121 Sec#63/266
1Y MDD	-50.08%	US#2,465/3,121 Sec#179/266
Trading
Volume	568,834 shares	US#2,748/3,121 Sec#256/266
Trading Value	$26M	US#2,492/3,121 Sec#209/266
Per Share
EPS	$17.40	US#116/3,121 Sec#4/266
BPS	$22.99	US#1,116/3,121 Sec#22/266